Amgen's strategic growth through M&A and R&D investments has led to a diversified portfolio. Find out why I give AMGN stock a ...

Amgen highlighted its robust performance in 2024, achieving 14 products annualizing over $1 billion in sales. CEO Robert Bradway emphasized the company's resilience in navigating challenges like ...

Repatha alone contributed a 40% sales increase ... Looking forward, Amgen maintains its 2024 revenue guidance between $33 billion and $33.8 billion, with a non-GAAP EPS range of $19.20 to $ ...

Success factors for Amgen involve strong product sales, effective cost management ... Revenue expectations for 2024 have been tightened to a range of $32.8 billion to $33.8 billion, up slightly ...

In his 13 years as CEO at Amgen, Robert Bradway has seen many of his counterparts at other major biopharma companies come and ...

With a label expansion for Uplizna pushing the drug into an untouched rare disease market, Amgen is getting its money’s worth ...

Amgen has gotten caught up in the broader market decline, but its business is unscathed. Its obesity drug sales are about to boom, making the stock look like a buy.